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a b s t r a c t
Viral diagnosis and discovery are receiving increasing emphasis with the recognition of their importance
in addressing the challenges of emerging infectious and chronic diseases, and the advent of antiviral
drugs with which to reduce the morbidity and mortality of viral infections. Here we review the status of
the ﬁeld including the use of molecular, proteomic and immunological assays for viral detection, social
media platforms for surveillance, and public health investments that may enable enhanced situational
awareness and insights into the origins of zoonotic viral diseases.
& 2015 Elsevier Inc. All rights reserved.
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Introduction
Two quotes from 1960 Nobel Laureate Peter Medawar are
particularly apt in introducing this paper on virus hunting: “A
virus is piece of bad news wrapped in protein” and “The human
mind treats a new idea the same way the body treats a strange
protein; it rejects it.” The ﬁrst is more often cited by clinicians and
virologists; however, the latter has proven to be more reliable.
Although viruses were once detected only in association with
tissue pathology, the advent of molecular methods, and speciﬁ-
cally high-throughput sequencing, has enabled the discovery of
useful viruses. The retroviral envelope gene syncitin, for example,
is critical to placental morphogenesis and may have contributed to
mammalian evolution (Mi et al., 2000). Marine phages continu-
ously lyse prokaryotes thereby releasing cellular components that
are essential to the growth of phytoplankton, regulation of the
global carbon cycle and may play roles in global climate change
(Suttle, 2007; Danovaro et al., 2011). Viruses and viral gene
products have also been harnessed in biotechnology and medicine.
In this paper we will focus on viral discovery, diagnostics and
surveillance in acute diseases; nonetheless, we ask the reader, in
the spirit of Medawar's second quote, to consider the currently
controversial concepts that viruses contribute to chronic disease as
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/yviro
Virology
http://dx.doi.org/10.1016/j.virol.2015.02.006
0042-6822/& 2015 Elsevier Inc. All rights reserved.
n Correspondence to: Center for Infection and Immunity, 722W 168th Street 17th
Floor, New York, NY 10032, United States.
E-mail address: Wil2001@columbia.edu (W.I. Lipkin).
Virology 479-480 (2015) 194–199
well as the potential role of viruses as tools for synthetic biology
and medicine.
Diagnostics
Viral diagnosis was not a prominent service function in clinical
microbiology laboratories until recently. This reﬂected resource
intensive aspects of viral diagnostics such as culture using several
cell lines, electron microscopy or serology as well as the fact that
results provided insights with minimal impact of clinical manage-
ment. The status of viral diagnostics has changed with the
introduction of antiviral drugs and the development of molecular
assays that can identify which patients will beneﬁt from speciﬁc
antiviral drugs, as well as monitor the adequacy of the responses
to those drugs. Additionally, as demonstrated during the course of
outbreaks of SARS in 2003, MERS in 2012 and Ebola in 2014, public
health practitioners and policy makers are increasingly reliant on
viral diagnostics to track emerging viral diseases and make
decisions concerning who to isolate and for how long to do so.
Despite the shift in diagnostics toward molecular assays, viral
culture continues to play an important role in virology because it is
essential to test drugs, the neutralization capacity of antibodies
and vaccine responses as well as to develop stocks of virus for
work in animal models. Some viruses can be propagated in
immortalized cell lines whereas others can only be grown in
primary or organotypical cultures. Still others require the use of
antibodies or RNAi to suppress innate immune responses or must
be inoculated into live animals such as suckling mice. Gastro-
intestinal samples can be particularly challenging in that they
typically contain more than one virus. We have seen many
examples where a virus better adapted to culture may outgrow a
virus that is more abundant in vivo, obscuring detection of the
latter. Accordingly, we prefer to use less biased molecular methods
for discovery and reserve culture for follow on studies.
Molecular assays
Molecular assays employed in clinical microbiology include poly-
merase chain reaction (PCR), isothermal ampliﬁcation, DNA micro-
arrays, in situ hybridization and sequencing. The most common are
real time PCR assays wherein the release of a ﬂuorescent molecule
during the course of DNA strand replication results in detection of a
single viral target. These assays are exquisitely sensitive, speciﬁc,
quantitative and inexpensive, and are used not only for differential
diagnosis but also to follow response to antiviral therapy. Portable
PCR systems have been developed for ﬁeld applications; nonetheless,
some investigators prefer isothermal ampliﬁcation tests that do not
require programmable thermal cyclers. PCR sensitivity is highest
when primers and probe sequences perfectly match the selected
single genetic target. Indeed, these assays may fail to detect related
viruses—a potentially daunting challenge in RNA virus infections
where high mutation rates are characteristic. Consensus PCR assays
wherein primers and/or probes contain wobble codes may succeed;
however, they are typically less sensitive than speciﬁc PCR assays.
Nested PCR tests that can employ consensus or speciﬁc primers in
two sequential ampliﬁcation reactions with either one (hemi-nested)
or two (fully nested) primers located 30 with respect to the ﬁrst
primer set may accommodate sequence variation and be as sensitive
as ﬂuorescent real time PCR assays. However, whereas in real time
assays reporter readings are taken indirectly without opening the
reaction vessels, nested PCR systems are prone to contamination
because of the transfer of ampliﬁed product from the ﬁrst to the
second nested reaction.
Multiplex PCR assays are increasing in popularity because they
can be used to simultaneously address a wide range of candidate
viral, bacterial, fungal and parasitic pathogens. This is particularly
important early in the course of infection when signs and symp-
toms of disease are less speciﬁc. However, multiplex assays can be
difﬁcult to establish because different primers and probes require
different reaction conditions for optimal performance. An additional
challenge is the limited repertoire of ﬁve ﬂuorescent reporter
molecules available for use in the most commonly employed clinical
instruments. One alternative platform (Luminex xTag) employs ﬂow
cytometry to detect multiple PCR ampliﬁcation products bound to
matching oligonucleotides that are attached to ﬂuorescent beads.
By combining multiplex PCR ampliﬁcation systems with various
protocols for direct or indirect (tag-mediated) bead hybridization of
the products, assay panels have been developed that detect more
than 20 different genetic targets. Other PCR platforms employ mass
spectroscopy to differentiate genetic targets based on product mass
(IRIDICA, Abbott) or the presence of tags conjugated to primers
used in PCR that vary in mass (Briese et al., 2005). Such systems can
detect up to 20 different genetic targets in a single reaction but are
typically 10–100 fold less sensitive than real time PCR.
Microarrays comprising millions of discrete oligonucleotide
probes have the potential to detect all known viruses as well as
viruses with limited homology to known viruses (Wang et al.,
2002; Palacios et al., 2007); however, as they currently depend on
a random (vs. speciﬁc) PCR ampliﬁcation step followed by hybri-
dization of the ﬂuorescently labeled product, microarrays are even
less sensitive than multiplex PCR systems. New platforms are in
development that will detect viral sequence binding through
changes in electrical conductance. These platforms will not require
ﬂuorescent scanners and may have improved sensitivity.
In situ hybridization is a method whereby nucleic acid probes
are used to detect the presence and cellular distribution of
complementary sequences in cultured cells or tissue sections. Its
primary applications are for work focused on pathogenesis or cell
biology rather than diagnostics.
High-throughput sequencing, also known as Next Generation
Sequencing, has transformed medicine and virology by enabling
viral discovery as well as diagnostics. Unlike PCR or array methods
where the breadth of agents interrogated is limited by the capacity
for multiplexing or known sequence data, high-throughput sequen-
cing has the potential to simultaneously detect not only all viruses,
but also bacteria, fungi and parasites. Furthermore, the time and
resources previously required to clone and sequence entire viral
genomes have been reduced from months to days. Over the past 10
years the cost has decreased 10,000 fold from $5000 per 1000
nucleotides in 2001 to $0.5 per 1000 nucleotides in 2012.
Platforms in current use analyze libraries of ampliﬁed nucleic
acids. However, some platforms in development will have the
capacity to directly sequence nucleic acid. Irrespective of the plat-
form, raw sequence reads are ﬁltered for quality and redundancy
before assembly into contiguous strings of sequence streams that
are aligned to sequences in databases using algorithms that search
for similarity at the nucleotide and deduced amino acid levels in all
six potential reading frames. The alignments allow identiﬁcation of
known and novel agents, as well as detection of genetic features
that may be associated with drug or vaccine resistance, or provide
insight into provenance and evolution.
Host response
Molecular diagnostic methods are sensitive, but do not serve in
instances where microbial nucleic acids are not present in an
accessible sample (e.g. the brain in encephalitis) or disease is
triggered by an agent that is no longer present. Serology comple-
ments molecular diagnostics by providing insights into a subject's
pathogen exposure history. It can test for the relevance of a discovery
made using molecular methods by indicating that whether an
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infection temporally correlates with the onset of disease. Serology
can also help target molecular investigation. This application has
become less important since the advent of inexpensive unbiased
high-throughput sequencing; however, immunohistochemistry and
serology were critical in focusing PCR studies that resulted in the
identiﬁcation of Sin Nombre virus (Nichol et al., 1993), Nipah virus
(Chua et al., 1999), and West Nile virus in New York City in 1999
(Briese et al., 1999). Although a wide range of diagnostic platforms
have been developed for detection of microbial nucleic acids,
methods for detection of host responses to pathogens have lagged.
Serological assays provide evidence that a host has encountered
and responded to a microbe through the activation of speciﬁc B-cells.
An activated B-cell can respond to femtomolar antigen concentra-
tions and generate up to 109 speciﬁc antibody molecules in a week;
hence, antibody assays have potential for extraordinary sensitivity.
Antibodies are also remarkably stable. To date most serology has
been performed using single antigenic target enzyme-linked immu-
nosorbent assays (ELISA). More recently, bead-based systems have
been employed that can address up to 100 antigenic targets
simultaneously (i.e., 100 individual pathogens, 100 individual anti-
genic targets for one pathogen, or some variation thereof). Addition-
ally, arrays are established that comprise spotted recombinant
proteins expressed in vitro in Escherichia coli, Saccharomyces cereve-
siae, baculoviruses, or in cell-free, coupled transcription-translation
systems. However, assay development is complex and time consum-
ing; hence, rapid response to an emerging pathogen is impractical.
Furthermore, none of these methods achieve the degree of multi-
plexing required to complement what has become standard in direct
nucleic acid detection systems.
Burbelo et al. (2010) have established a sensitive and quanti-
tative liquid phase format assay for proﬁling antibody responses to
antigen panels. Luciferase immunoprecipitation system (LIPS)
assays express viral open reading frames fused to an enzyme
reporter, Renilla luciferase, in eukaryotic cells. Fusion proteins
harvested under native conditions are mixed with serum samples
and immunoprecipitated using protein A/G magnetic beads. No
secondary antibodies are required because the primary antibodies
in serum bind directly to beads through interaction of their Fc
region with staphylococcal protein A and streptococcal protein G.
Protein A binds with high afﬁnity to the Fc region of human (IgG1,
IgG2, IgM, IgA, IgE), rabbit, guinea pig, dog and monkey immu-
noglobulins. Protein G binds with high afﬁnity to the Fc region of
human, rabbit, pig, horse, cow, mouse, goat and monkey immu-
noglobulins. Thus, a single LIPS assay can be used to screen many
different species for evidence of exposure to infectious agents or
for successful vaccination. Establishment of a new LIPS assay
typically requires 10–15 days from the time that genomic
sequence data becomes available. Over the past two years, we
and our colleagues have designed and implemented LIPS assays for
investigation of the pathogenesis and epidemiology of astro-
viruses, picornaviruses, parvoviruses, orbiviruses, hepaciviruses,
pegiviruses, and to proﬁle exposure histories of individuals with
HIV/AIDS.
Although LIPS technology enables rapid development of ser-
ological assays for virology, it is not a multiplex platform. One
solution that can address this gap is phage display systems
wherein libraries of peptides are reacted with sera and those that
bind are characterized through DNA sequencing. Another potential
solution is programmable peptide chip technology, an approach
analogous to that used in building DNA microarrrays but sub-
stituting oligopeptides for oligonucleotides. Commercial platforms
are in development that comprise millions of oligopeptide features
in a single assay. Such platforms have the potential to enable
detection of humoral immune responses to all known vertebrate
viruses, allowing surveys for exposure to all known human viral
pathogens as well as those that emerge through zoonotic
transmission. Through microﬂuidics it may become feasible to
probe an individual's immunological memory, providing insights
that will facilitate differential diagnosis and research into the role
of speciﬁc infectious agents in acute and chronic diseases.
In clinical microbiology, serology is typically interpreted to
mean the study of B-cell responses to infectious agents. However,
it can be taken in a larger sense to represent any biomarker for
infection that is present in serum. The most common approaches
are bead-based assays for detection and quantitation of cytokines
and chemokines that indicate immune activation consistent with
infection. The initial hope was that patterns of expression would
be sufﬁciently distinctive as to allow differential diagnosis by
serving as surrogate assays for infection with speciﬁc infectious
agents. This has not yet proven true; nonetheless, cytokine proﬁles
have been used to for insights into pathogenesis and prognosis (e.
g., cytokine storm), indications of genetic differences underlying
difference in innate and adaptive immunity and as biomarkers for
viral reactivation.
Even more robust than the cytokine platforms currently limited
to analysis of 50–70 molecules are the biomarker discovery plat-
forms that quantitate levels of speciﬁc host RNA populations in
tissues and body ﬂuids through use of microarrays or RNA sequen-
cing (transcriptomics), host proteins (proteomics) or products of
metabolic processes (metabolomics) through mass spectroscopy.
Together these assays comprise the components of the ﬁeld of
systems biology wherein investigators integrate large datasets for
insights into the impact of the environmental perturbations on
function at the level of individual cells, organs or the entire
organism. These insights have the potential to lead to treatment
strategies that modify host response rather than targeting the
infectious agent. They can also be used to identify genetic and
epigenetic determinants of host response that inﬂuence the out-
come of infection. Recently, such research in genetically character-
ized mice infected with Ebola virus provided clues that may help
explain differences in human vulnerability to this hemorrhagic
fever virus (Rasmussen et al., 2014).
Viral discovery and surveillance
Viruses represent the largest and most genetically diverse
source of biomass on earth (Suttle, 2005). Suttle has estimated
that the ocean alone contains more than 1030 viruses, with an
abundance that exceeds that of archea and bacteria by at least 15-
fold. Characterization of the global virome is clearly an insur-
mountable task; fortunately, our focus here is on the only slightly
less daunting challenge of characterizing the repertoire of human
viral pathogens.
Zoonotic diseases and globalization
The vast majority of emerging infectious diseases, including such
examples as HIV/AIDS, Nipah, SARS, MERS and Ebola, represent
infections with viruses that jump species barriers from wildlife or
domestic animals to humans. Although the role of animals in
emerging infectious diseases has been known for decades, it is only
recently that it was formally recognized by the establishment of the
One Health Initiative (http://www.onehealthinitiative.com/), a
movement to enhance collaboration between health care profes-
sionals, public health practitioners and policy makers. The emer-
gence of zoonotic diseases can be attributed to behaviors that result
in increased frequency of human exposure to wildlife through
incursion into wildlife habitats or consumption of wildlife products
(bushmeat) as well as conditions that facilitate human-to-human
transmission of infectious agents such as high population density
and mass gatherings. A warming climate may also increase the
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geographic range of phlebotomous insects like mosquitoes and ticks
that serve as reservoirs and vectors for infectious agents.
Globalization of travel and trade is also an important factor in the
emergence and dissemination of viral diseases. Nonstop ﬂights of less
than 24 h connect the world's major airports. Legal and illegal
trafﬁcking of animal products and exotic pets can result in inad-
vertent importation of exotic infectious diseases once restricted to
the developing world. The annual trafﬁc in bushmeat through JFK
airport alone in New York is estimated at more than 90 million tons.
Our analysis of bushmeat seized at JFK revealed evidence of infection
with retroviruses and herpesviruses (Smith et al., 2012). Illegal
importation of birds, primates and rodents has been linked to
outbreaks of exotic viral diseases. The most prominent example
was in 2003 when 35 people were infected with monkeypox carried
from Africa by a Gambian pouched rat, brought in through the illegal
pet trade (Di Giulio and Eckburg, 2004).
Several programs have been established with the goal of
proactively addressing the challenge of infectious disease emer-
gence through targeted surveillance in global ‘hotspots’ of emer-
gence. The largest is the Emerging Pandemics Threat Program (EPT),
administered by the United State Agency for International Develop-
ment (USAID). The goals of the EPT, and of programs sponsored by
other governments and foundations are to understand the under-
lying causes of disease emergence and spread in people through
enhanced local wildlife surveillance, and the delivery of new plat-
forms for surveillance and discovery close to the source of pathogen
emergence.
Sampling: how much is enough?
A question that arises frequently in discussions of viral surveil-
lance and discovery is how much sampling would be required to
obtain a comprehensive inventory. As a case study, we recently
addressed this question by repeatedly sampling a mammalian
wildlife host known to harbor emerging zoonotic pathogens (the
Indian Flying Fox, Pteropus giganteus), and used PCR with degen-
erate viral family-level primers to discover and analyze the
occurrence patterns of viruses representing nine viral families.
Asymptotic viral richness, estimated by adapting statistical tech-
niques more commonly used to estimate biodiversity in verte-
brates and plants, indicated that P. giganteus likely contained at
least 58 viruses in these nine families. A simple extrapolation to all
5486 described mammalian species then indicated that a mini-
mum of 320,000 viruses await discovery. This ﬁnding then allowed
us to consider an economic analysis to estimate the global cost of
discovering these viruses, or some portion of them. With rapidly
diminishing returns in discovery (as a function of effort), we
demonstrated that 85% of the estimated diversity could be achieved
for a fraction of the cost of discovering them all, highlighting the
potential usefulness of this approach in reﬁning targeted public
health surveillance.
Bioterrorism and synthetic threats
Naturally emerging hemorrhagic fevers and respiratory diseases
are the primary foci in viral biosurveillance for public health; none-
theless, bioterrorism concerns also drive policy. Until the close of the
Cold War in the late 1980s, the major concern was bioweapons
research at the State Research Center of Virology and Biotechnology
VECTOR in Novosibirsk. Concern thereafter shifted to the Middle East
and accelerated after the twin towers aerial attack in 2001 and the
subsequent anthrax attacks. One result of these events in the U.S was
the establishment of new BSL-3 and BSL-4 laboratories and the NIAID
Regional Centers for Biodefense. These enabled the recruitment of
scientists to develop diagnostics, drugs and vaccines for high-threat
pathogens. An early objective of the centers was to address the
challenge of genetically modiﬁed pathogens; however, as building
such pathogens required resources and expertise that were then
present in only a few highly specialized laboratories in the indus-
trialized world, this concern rapidly receded to allow a focus on
emerging infectious diseases. In the intervening years, synthetic
biology has become more straightforward and there is again a need
to include surveillance for high-threat engineered pathogens. These
may be the products of bioweapon development by rogue scientists
or of legitimate gain-of-function research with inadvertent release.
Pathogenesis and proof of causation
As more investigators become involved in the ﬁeld of pathogen
discovery, it is becoming increasingly important to develop criteria
for establishing a causative relationship between the presence of a
virus and a disease. The best-known criteria for proof of causation
are known as Koch's postulates. These criteria require that an
agent be present in every case of the disease, be speciﬁc for the
disease and sufﬁcient to reproduce the disease after culture and
inoculation into a naive host. Koch's postulates remain the ideal;
nonetheless, there are instances where they cannot be fulﬁlled
because there is no culture system for propagating the virus or
animal model for testing pathogenicity.
We have developed a hierarchy of conﬁdence in the relevance of a
viral discovery (Fig. 1) (Lipkin, 2013). Level 1, a possible causal
relationship, pertains when there is evidence of exposure to an
infectious agent in one or more individuals with disease. This
evidence might be a virus recovered in culture or visualized by
electron microscopy, or a viral nucleic acid or protein. Level 2, a
probable causal relationship, pertains when the link is biologically
plausible because evidence of infection is found in many individuals
with the same disease, there is precedent for a similar disease caused
by a similar virus in either the same or a similar host, the virus (or its
gene products) are found at high concentration at the site of
pathology, or there is a host response consistent with recent
exposure (virus-speciﬁc IgM or rise in virus-speciﬁc IgG). Level 3, a
conﬁrmed causal relationship, requires fulﬁllment of Koch's postulates
or evidence that the use of speciﬁc drugs, antibodies or vaccines can
prevent or mitigate disease.
Host factors can have a profound impact on susceptibility to
infection and the consequences of infection. Agents that normally
cause no or only mild disease can have severe consequences in
individuals with immunodeﬁciencies, due to genetic mutations,
age, malnutrition, HIV/AIDS or complications of cancer treatment
or transplantation. Thus, the principle whereby investigators look
for clusters of disease associated with candidate pathogens must
be expanded from simple models where cases are closely linked in
time and space to include clusters based on other demographic
factors. A classic example is the association between progressive
multifocal leuokoencephalopathy due to JC virus and immunosup-
pression in the context of HIV/AIDS or therapy for multiple
sclerosis. Pathogenic mechanisms may be direct or indirect, readily
manifest or subtle. Viruses can cause tissue damage as a direct
result of replication or via innate or adaptive immune responses to
microbial gene products. Microorganisms can also induce neopla-
sia through interference with cell cycle controls. Although not yet
conﬁrmed in human disease, work in animal models indicates that
viruses can reduce the production of hormones or neurotransmit-
ters that are vital to normal host physiology, and that they can do
so without causing any apparent cell or organ damage.
Some of the most intriguing concepts in viral pathogenesis
involve complex mechanisms that include infection with other
microbes (other viruses, bacteria or parasites) or a timing compo-
nent. The most straightforward instances are those where viral
infection results in immunosuppression that enables opportunistic
infections. The most dramatic example is HIV/AIDS where disease
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may present with Pneumocystis carinii pneumonia, central nervous
system infection with Toxoplasma gondii or Cryptococcus neofor-
mans, or Kaposi sarcoma. A related phenomenon is expansion of
the enteric virome in Rhesus macaques infected with SIV (Handley
et al., 2012). Bacterial superinfection has been implicated in
increased morbidity and mortality in inﬂuenza infection (Wang
et al., 2002; Palacios et al., 2009). Helminth infection in mice can
result in reactivation of gamma herpesviruses through induction
of IL4 (Reese et al., 2014).
We and others have built models of neurodevelopmental
disorders based on gestational viral infections wherein the timing
of maternal inoculation with inﬂuenza virus or the viral mimic
polyinosine/cytosine results in abnormalities in social and loco-
motor behaviors in the offspring (Malkova et al., 2012). These
effects are associated with a reduction in neuronal stem cells that
is found in wildtype mice but not in Toll 3 receptor knockout mice
and can be abrogated through the use of nonsteroidal anti-
inﬂammatory drugs (De Miranda et al., 2010).
Our ability to detect associations between environmental
exposures and disorders that may only manifest in later life
depends on access to prospectively collected questionnaire data
and clinical samples in large cohorts. The Center for Infection and
Immunity works with the Norwegian Institute of Public Health in a
program that includes such questionnaire data and samples
obtained beginning at the ﬁrst prenatal visit (approximately 17
weeks gestation). The cohort represents 117,000 mothers and their
children, and is linked to a national patient registry that records all
clinic and hospital visits (Stoltenberg et al., 2010). In reviewing
such registries, investigators have an unprecedented resource with
which to examine how infection, intoxication and genetic and
epigenetic factors inﬂuence risk and resilience for diseases in any
organ system.
Social media
The development of the Internet and of web protocols that
facilitate exchange of user-generated content offers an unprecede-
nted opportunity for global biosurveillance. The ﬁrst such program
was ProMED-mail (Programme for Monitoring Emerging Infectious
Diseases) (www.promedmail.org). Since 1994, ProMED-mail has con-
tinuously collected submissions that report conﬁrmed or suspected
new or evolving outbreaks and epidemics. Submissions are screened
and commented upon by a panel of experts, then distributed in several
languages to a listserv comprising more than 60,000 subscribers in
185 countries. GPHIN (Global Public Health Intelligence Network)
established in collaboration with the World Health Organization
Global Alert Response Network scans global media for information
concerning disease outbreaks, food and water contamination, bioter-
rorism, natural disasters, and reports concerned with the safety of
products, drugs and medical devices (Mykhalovskiy and Weir, 2006).
Unlike ProMED-mail, which is a freely available, GPHIN is a fee-based
subscription service. HealthMap collects reports from professional and
social media including crowd sourced information contributed via its
website or smart phone-based apps such as Outbreaks Near Me and
Individual case report 
rt Social media repo
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multiplex assay
High-throughput 
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Serology 
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Fig. 1. A staged strategy for viral discovery. The process initiates with the report of illness consistent with a case or outbreak of infectious disease and collection of
appropriate samples (tissue, blood, cerebrospinal ﬂuid, urine, feces or respiratory secretions). In the discovery phase, samples are analyzed using a syndrome-speciﬁc
molecular assay, most commonly based on the polymerase chain reaction. If the multiplex assay yields a candidate viral sequence, the process advances to the conﬁrmation
phase. If not, samples are subjected to unbiased high-throughput sequence analysis to identify potential pathogen candidates. In the conﬁrmation phase, the relationship of
the virus to disease is tested by examining the site of viral replication and determining whether disease is associated with an adaptive immune response to the virus. In the
extension phase, efforts are made to propagate the virus in cultured cells or animals to enable research in cell biology and pathogenesis, and to develop interventional
strategies including antiviral therapies and vaccines.
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Google Flu Trends. Data are then assembled into a user-friendly
graphical interface that provides real-time updates of disease, with
hyperlinks to more detailed information (http://healthmap.org/en/).
There is as yet no comprehensive system that collects information
concerning medical service utilization, death records, diagnostic data,
and prescription and over-the-counter drug use. However, the future
of biosurveillance will almost certainly include all of the above.
Modeling viral emergence
Improvements in diagnostics and discovery methods and the
early detection of outbreaks using social media hold the promise
of reducing the mortality, morbidity and health care costs due to
emerging viral diseases. Better still would be a proactive strategy
in which surveillance and discovery efforts are focused at sites and
in hosts wherein viral pathogens of humans are likely to emerge
and re-emerge. The development of high resolution, global scale
data sets of human demographics, agricultural production, land-
use change, travel and trade patterns, climate and wildlife dis-
tribution has provided tools that may ultimately enable accurate
predictive modeling; nonetheless, it should be acknowledged that
to date no viral human outbreak has been predicted using
algorithms prior to a cross-species jump. These authors have not
ruled out the possibility that such algorithms will be developed
but believe that our best defense against emerging viral diseases is
to develop local capacity in laboratory diagnostics and outbreak
response as well as a robust global surveillance system wherein
data and samples are shared to promote public health.
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